Rezolute
Specializing in the development of drug therapies for patients with metabolic and orphan diseases.
Launch date
Employees
Market cap
€264m
Enterprise valuation
€194m (Public information from Sep 2024)
Share price
$4.87 RZLT
Louisville Kentucky (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 16.4m | 22.7m |
| % growth | - | - | - | - | - | - | 38 % |
| EBITDA | (20.3m) | (22.3m) | (41.5m) | (51.8m) | - | - | - |
| Profit | (20.3m) | (20.9m) | (41.1m) | (51.8m) | (63.0m) | (57.3m) | (72.7m) |
| % profit margin | - | - | - | - | - | (349 %) | (320 %) |
| EV / revenue | - | - | - | - | - | 11.9x | 8.0x |
| EV / EBITDA | -1.3x | -5.3x | -2.6x | -1.4x | - | - | - |
| R&D budget | 14.5m | 15.0m | 32.5m | 43.8m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $6.0k | Seed | |
| N/A | N/A | IPO | |
| N/A | $1.4m | Post IPO Equity | |
| N/A | $2.0m | Post IPO Equity | |
| N/A | $4.3m | Post IPO Equity | |
$12.0m | Post IPO Equity | ||
| N/A | $6.7m | Post IPO Equity | |
* | N/A | $5.0m | Convertible |
* | $25.0m | Post IPO Equity | |
$41.0m | Post IPO Equity | ||
$30.0m | Post IPO Debt | ||
| N/A | $55.0m | Post IPO Equity | |
* | N/A | $130m | Private Placement VC |
* | N/A | $60.0m | Post IPO Equity |
* | N/A | $6.7m | Post IPO Equity |
| Total Funding | €123m | ||
Related Content
Recent News about Rezolute
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.